Aytu BioScience, Inc. (AYTU) Reaches $1.46 52 Week Low; EXOSPHERE TECHNOLOG (ESPH) SI Increased By 1.66%

February 13, 2018 - By Vivian Park

The stock of Aytu BioScience, Inc. (NASDAQ:AYTU) hit a new 52-week low and has $1.34 target or 8.00% below today’s $1.46 share price. The 6 months bearish chart indicates high risk for the $7.26M company. The 1-year low was reported on Feb, 13 by Barchart.com. If the $1.34 price target is reached, the company will be worth $580,480 less. The stock decreased 18.44% or $0.33 during the last trading session, reaching $1.46. About 74,908 shares traded. Aytu BioScience, Inc. (NASDAQ:AYTU) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

EXOSPHERE TECHNOLOG (OTCMKTS:ESPH) had an increase of 1.66% in short interest. ESPH’s SI was 404,500 shares in February as released by FINRA. Its up 1.66% from 397,900 shares previously. With 570,400 avg volume, 1 days are for EXOSPHERE TECHNOLOG (OTCMKTS:ESPH)’s short sellers to cover ESPH’s short positions. It closed at $0.014 lastly. It is down 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Ecosphere Technologies, Inc., a technology development and intellectual property licensing company, develops environmental solutions for the water, agriculture, energy, and industrial markets worldwide. The company has market cap of $2.55 million. The firm offers Ozonix water treatment technology, an advanced oxidation process that is designed to treat and recycle industrial wastewater without the use of toxic chemicals. It currently has negative earnings. The Company’s Ozonix water treatment technology is used in oil and natural gas, mining, agriculture, energy, food and beverage, industrial, and marine, as well as for municipal wastewater treatment applications.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company has market cap of $7.26 million. The firm markets Natesto for the treatment of hypogonadism in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It currently has negative earnings. It is also involved in commercializing of the RedoxSYS System for research use in various applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>